1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
- Contribution to journal › Article
- 2016
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
- Contribution to journal › Article
- 2014
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
- Contribution to journal › Article
- 2012
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Jerkeman, Mats LU ; Raty, Riikka ; Andersen, Niels S. ; Pedersen, Lone B. ; Eriksson, Mikael LU
; Nordstrom, Marie
and Kimby, Eva
, et al.
(2012)
In British Journal of Haematology
158(3).
p.355-362
- Contribution to journal › Article
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Raty, Riikka ; Jerkeman, Mats LU ; Eriksson, Mikael LU
; Nordstrom, Marie
; Kimby, Eva
; Boesen, Anne Marie
and Nilsson-Ehle, Herman
, et al.
(2010)
In Blood
115(8).
p.1530-1533
- Contribution to journal › Article
- 2009
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
- Contribution to journal › Article
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Andersen, Niels S. ; Pedersen, Lone B. ; Jerkeman, Mats LU ; Eriksson, Mikael LU
; Nordstrom, Marie
; Kimby, Eva
and Boesen, Anne Marie
, et al.
(2008)
In Blood
112(7).
p.2687-2693
- Contribution to journal › Article
- 2002
-
Mark
Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis.
Larramendy, Marcelo L ; Niini, Tarja ; Elonen, Erkki ; Nagy, Bálint ; Ollila, Juha ; Vihinen, Mauno LU
and Knuutila, Sakari
(2002)
In Haematologica
87(6).
p.569-577
- Contribution to journal › Article